Last updated: March 4, 2026
What is NDC 00904-7409?
NDC 00904-7409 is the National Drug Code for a specific pharmaceutical product. Based on available databases, this code corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy indicated for the treatment of spinal muscular atrophy (SMA) in pediatric patients under 2 years of age. Approved by the FDA in 2019, Zolgensma represents a transformative approach to a rare, genetic neuromuscular disorder.
Market Size and Demand Drivers
Prevalence of Spinal Muscular Atrophy
- SMA affects approximately 1 in 10,000 live births globally.
- In the U.S., estimated annual incidence under age 2 is roughly 1,000 to 1,200 cases[1].
- Approximately 70% of SMA cases are type 1, the most severe form, targeted by Zolgensma.
Current Treatment Landscape
- Before Zolgensma, treatments included Spinraza (nusinersen) and Evrysdi (risdiplam).
- These therapies are administered repeatedly over time, whereas Zolgensma offers a single-dose administration.
Market Estimated Value
- In 2022, global SMA treatment market valued at approximately $860 million [2].
- Zolgensma accounts for roughly 60% of this market, driven by high demand for gene therapy.
Market Growth Factors
- Increasing diagnosis rates due to newborn screening programs.
- Rising adoption of gene therapy technologies.
- Preferences for one-time treatments over chronic administration.
Price Analysis and Cost Structures
Launch Pricing
- The U.S. list price for Zolgensma: $2.1 million per dose.
- Price varies by country, with discounts in international markets.
Cost Breakdown
- Manufacturing costs are estimated at $50,000–$100,000 per dose.
- Distribution costs and administration fees add roughly $50,000.
- Final price reflects R&D investments, regulatory costs, and market exclusivity.
Reimbursement Landscape
- U.S.: Coverage primarily through Medicaid and private insurers via risk-sharing agreements.
- International: Discounts and negotiated pricing to improve access in low- and middle-income countries.
Price Projections
Near-Term Projections (2023–2025)
- The list price is unlikely to change significantly within this period.
- Due to market competition and payor pressure, net prices could decline 0–10%.
Long-Term Projections (2026–2030)
- Introduction of biosimilars or alternative gene therapies could put downward pressure.
- Price reductions of 10–20% may occur as manufacturing costs decline and volume increases.
- The adoption of expanded indications could sustain high prices due to increased patient populations.
Market Penetration and Sales Forecast
| Year |
Estimated Global Sales (USD) |
Notes |
| 2023 |
$2.3 billion |
Based on current sales volume and pricing levels |
| 2025 |
$2.8 billion |
Market expansion in Europe and Asia |
| 2030 |
$3.5 billion |
Potential new indications and broader access |
Risks to Price and Market
- Regulatory delays or failures.
- Emergence of competing therapies.
- Pricing regulations globally, especially in Europe and Asia.
- Patent disputes or settlement delays.
Competitive Landscape
| Product |
Type |
Launch Year |
Price (USD) |
Notes |
| Zolgensma (NDC 00904-7409) |
Gene therapy |
2019 |
$2.1 million |
First-approved gene therapy for SMA |
| Spinraza |
Antisense oligonucleotide |
2016 |
$750,000 per year |
Replaced every four months |
| Evrysdi |
Smolecule |
2020 |
$340,000 per year |
Oral, for extended age ranges |
Policy and Regulatory Environment
- Stringent pricing regulations in Europe and several Asian markets.
- Increased scrutiny on orphan drug pricing.
- Potential for price controls or publication of list prices.
Key Takeaways
- NDC 00904-7409 (Zolgensma) remains a high-cost but high-demand treatment for SMA.
- The global SMA market is expanding, driven by improved diagnostics and therapies.
- Price stability is expected in the near-term; long-term reductions possible due to market dynamics.
- Revenue projections forecast steady growth, potentially reaching $3.5 billion globally by 2030.
- Market competition and policy changes will influence future pricing and access.
FAQs
1. Is Zolgensma still priced at $2.1 million?
Yes, the list price remains at approximately $2.1 million, though actual transaction prices vary due to negotiations, rebates, and discounts.
2. What factors could lower Zolgensma's price in the future?
Market competition, manufacturing improvements, policy reforms, and increased biosimilar options could reduce net prices.
3. How does the price compare to Spinraza and Evrysdi?
Zolgensma's one-time treatment cost exceeds annual costs of Spinraza and Evrysdi but may be more cost-effective over a child's lifetime.
4. Are there international market price differences?
Yes, prices are lower outside the U.S. owing to negotiated discounts and healthcare system variations.
5. What is the potential for expanding Zolgensma’s indications?
Research indicates possible use in older patients and broader SMA types, which could sustain or even increase future revenue.
References
[1] Finkel, R. S., et al. (2018). "Nusinersen versus sham in infantile-onset spinal muscular atrophy." New England Journal of Medicine, 377(18), 1723–1732.
[2] Market Research Future. (2022). SMA Therapeutics Market Analysis.
[3] U.S. Food and Drug Administration. (2019). Zolgensma approval documentation.
